No. of all diabetic participants (%): 733 (100%) | No. of HBV DNA negative subjects (%): 714 (97.4%) | No. of HBV DNA positive subjects (%): 19 (2.6%) |
Adjusted OR (95% CI) | P-value | |
---|---|---|---|---|---|
Age groups (years) | |||||
26–30 | 16 (2.2%) | 16 (100.0%) | 0 (0.0%) | 1.0 | |
31–40 | 67 (9.1%) | 67 (100.0%) | 0 (0.0%) | 0.00 | 0.99 |
41–50 | 143 (19.5%) | 137 (95.8%) | 6 (4.2%) | 0.00 | 0.99 |
51–60 | 284 (38.7%) | 281 (98.9%) | 3 (1.1%) | 0.24 (0.06–0.99) | 0.05 |
61–70 | 147 (20.1%) | 141 (95.9%) | 6 (4.1%) | 3.99 (0.98–16.2) | 0.05 |
≥ 71 | 76 (10.4%) | 72 (94.7%) | 4 (5.3%) | 1.31 (0.36–4.77) | 0.69 |
Gender | |||||
Male | 256 (34.9%) | 252 (98.4%) | 4 (1.6%) | 1.0 | |
Female | 477 (65.1%) | 462 (96.9%) | 15 (3.1%) | 2.045 (0.67–6.23) | 0.208 |
FBS (mg/dL) | |||||
≤ 115 | 128 (17.5%) | 124 (96.9%) | 4 (3.1%) | 1.0 | |
116–125 | 89 (12.1%) | 87 (97.8%) | 2 (2.2%) | 0.8 (0.26–2.50) | 0.7 |
≥ 126 | 516 (70.4%) | 503 (97.5%) | 13 (2.5%) | 1.12 (0.25–5.07) | 0.88 |
Cholesterol (mg/dL) | |||||
≤ 200 | 403 (55.0%) | 391 (97.0%) | 12 (3.0%) | 0.69 (0.19–2.49) | 0.57 |
201–240 | 186 (25.4%) | 182 (97.8%) | 4 (2.2%) | 0.97 (0.213–4.39) | 0.96 |
≥ 241 | 144 (19.6%) | 141 (97.9%) | 3 (2.1%) | 1.0 | |
TG (mg/dL) | |||||
≤ 150 | 228 (31.1%) | 219 (96.0%) | 9 (4.0%) | 1.0 | |
151–200 | 239 (32.6%) | 232 (97.1%) | 7 (2.9%) | 0.278 (0.1–1.04) | 0.06 |
≥ 201 | 266 (36.3%) | 263 (98.9%) | 3 (1.1%) | 0.378 (0.1–1.48) | 0.16 |
ALT levels (IU/L) | |||||
≤ 24 | 324 (44.2%) | 318 (98.1%) | 6 (1.9%) | 1.0 | |
25–40 | 256 (34.9%) | 248 (96.9%) | 8 (3.1%) | 1.71 (0.59–4.99) | 0.33 |
41–80 | 130 (17.7%) | 128 (98.5%) | 2 (1.5%) | 0.48 (0.10–2.31) | 0.36 |
≥ 81 | 23 (3.1%) | 20 (87.0%) | 3 (13.0%) | 9.60 (1.51–61.07) | 0.02 |
AST levels (IU/L) | |||||
≤ 24 | 464 (63.3%) | 453 (97.6%) | 11 (2.4%) | 1.0 | |
25–40 | 187 (25.5%) | 182 (97.3%) | 5 (2.7%) | 0.88 (0.31–2.58) | 0.82 |
41–80 | 78 (10.6%) | 75 (96.2%) | 3 (3.8%) | 0.61 (0.34–2.23) | 0.45 |
≥ 81 | 4 (0.5%) | 4 (100.0%) | 0 (0.00%) | 0.00 | 0.99 |